ACET
Adicet Bio, Inc.
There isn't enough reported data to score ACET yet.
ACET Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ACET's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
ACET PE Valuation
ACET has no meaningful PE right now: it lost money over the past year.
ACET Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect ACET's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
ACET Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$16.99 | +$3.01 |
| Q2 2026 | -$19.87 | +$0.93 |
| Q1 2026 | -$23.32 | -$2.68 |
| Q4 2025 | -$26.40 | -$5.12 |
| Q3 2025 | -$20.00 | +$7.20 |
| Q2 2025 | -$20.80 | +$19.52 |
| Q1 2025 | -$20.64 | +$26.40 |
| Q4 2024 | -$21.28 | +$31.68 |
ACET is still losing money, but far less than before: $16.99 per share over the past year, against $264.32 at its worst in late 2019.
ACET Quarterly Revenue
ACET Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$18M | +$4.5M |
| Q2 2026 | -$20M | +$6.7M |
| Q1 2026 | -$21.5M | +$5.4M |
| Q4 2025 | -$20.9M | +$3.4M |
| Q3 2025 | -$22.5M | -$109K |
| Q2 2025 | -$26.7M | -$3M |
| Q1 2025 | -$26.9M | -$3.8M |
| Q4 2024 | -$24.3M | -$655K |
ACET has burned cash in almost every quarter: −$80M over the past year, against −$100M the year before.
ACET Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +143 shares |
| 1 year | +89% | +5.1M shares |
| 3 years | +300% | +8.1M shares |
| 5 years | +3201% | +10.4M shares |
ACET has 11M diluted shares, up 89% from a year ago.
ACET Net Leverage
ACET's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ACET Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.3 | Oversold |
| Stochastic | 1.8 | Oversold |
ACET's weekly RSI is 26 (oversold) and its Stochastic is 2 (oversold).
ACET PE vs Healthcare Sector
ACET has no meaningful PE right now: it lost money over the past year.
ACET Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.89 | 40% below |
| 20 week MA | $7.24 | 60% below |
| 50 week MA | $7.58 | 61% below |
| 100 week MA | $9.94 | 71% below |
| 200 week MA | $28.0 | 90% below |
ACET is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
ACET Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $147.8 | $229.6 | +55% |
| 2021 | $229.6 | $254.7 | +11% |
| 2022 | $254.7 | $126.9 | -50% |
| 2023 | $126.9 | $30.2 | -76% |
| 2024 | $30.2 | $14.8 | -51% |
| 2025 | $14.8 | $8.32 | -44% |
| 2026 YTD | $8.32 | $2.93 | -65% |
ACET has finished four years in a row lower, and it's down 65% so far in 2026.